DiaMedica Therapeutics Inc
$ 8.55
2.89%
24 Feb - close price
- Market Cap 432,764,000 USD
- Current Price $ 8.55
- High / Low $ 8.63 / 8.28
- Stock P/E N/A
- Book Value 0.99
- EPS -0.71
- Next Earning Report 2026-03-16
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.38 %
- ROE -0.64 %
- 52 Week High 10.42
- 52 Week Low 3.19
About
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Analyst Target Price
$15.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-12 | 2025-08-12 | 2025-05-06 | 2025-03-17 | 2024-11-11 | 2024-08-07 | 2024-05-08 | 2024-03-19 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-28 |
| Reported EPS | -0.17 | -0.18 | -0.18 | -0.18 | -0.15 | -0.13 | -0.14 | -0.14 | -0.12 | -0.16 | -0.2 | -0.14 |
| Estimated EPS | -0.17 | -0.19 | -0.18 | -0.1725 | -0.15 | -0.16 | -0.16 | -0.14 | -0.13 | -0.18 | -0.16 | -0.14 |
| Surprise | 0 | 0.01 | 0 | -0.0075 | 0 | 0.03 | 0.02 | 0 | 0.01 | 0.02 | -0.04 | 0 |
| Surprise Percentage | 0% | 5.2632% | 0% | -4.3478% | 0% | 18.75% | 12.5% | 0% | 7.6923% | 11.1111% | -25% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-16 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.17 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DMAC
2026-02-24 14:22:59
DiaMedica Therapeutics Inc. announced its participation in three upcoming investor conferences in March 2026. Company management, including CEO Rick Pauls and Chief Medical Officer Julie Krop, will engage in fireside chats and presentations at events hosted by TD Cowen, Barclays, and Leerink Partners to discuss their clinical-stage biopharmaceutical developments. The company focuses on novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke with their lead candidate DM199.
2026-02-15 12:57:39
Insiders at DiaMedica Therapeutics Inc. have significantly increased their holdings by US$58.4 million over the last year, indicating optimism about the company's future prospects. Notable purchases include US$10 million by Thomas von Koch and US$15 million by Jan Stahlberg, demonstrating confidence despite the stock price being higher than the average buy price. Insiders now own 47% of the company, valued at US$216 million, aligning their interests with other shareholders.
2026-02-07 12:59:06
DiaMedica Therapeutics (NASDAQ:DMAC) has received a consensus "Moderate Buy" rating from six analysts, with an average one-year price target of $12.33. Shares opened at $8.14, and the company recently missed EPS estimates, reporting ($0.17) for the quarter. Insider activity shows a significant purchase by major shareholder Jan Stahlberg, who acquired 240,352 shares, increasing his stake to over 8.3 million shares.
2026-01-24 12:57:32
Insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) now own 47% of the company's shares. This significant ownership suggests a vested interest in the company's growth, especially following recent insider purchases and a 12% stock gain. The top five shareholders collectively hold 52% of the company, with individual insiders making up the largest group.
2026-01-24 04:28:33
Cantor Fitzgerald analyst Joshua Schimmer maintained a Buy rating for Diamedica Therapeutics (DMAC) with a price target of $25.00, while the company's shares closed at $7.97. Despite a reported quarterly GAAP net loss of $8.62 million, corporate insider sentiment for DMAC stock is positive, marked by significant insider share purchases. The overall Street consensus for Diamedica Therapeutics is a Strong Buy with an average price target of $17.00.
2026-01-22 17:39:47
Insiders at DiaMedica Therapeutics Inc. (NASDAQ:DMAC) now collectively own 47% of the company's shares, demonstrating a strong vested interest in its growth. This significant insider ownership is highlighted following a 12% stock gain in the past week. Institutional investors also hold a substantial stake, and the top 5 shareholders combined own 52% of the company.
